In this issue:
Oncolytic immunotherapy with nivolumab in MIBC
Explaining diametric results of immunotherapy in urothelial cancer trials
LITESPARK-003: belzutifan + cabozantinib in advanced clear-cell RCC
Nivolumab + ipilimumab in metastatic variant histology RCC
TIVO-3: tivozanib vs sorafenib for ICIrefractory advanced RCC
A first-in-human study of an anti-TMEFF2 bispecific in mCRPC
CheckMate 914: Adjuvant nivolumab dose not prolong DFS in localised RCC
Bladder preserving chemoradiation for BCG-refractory T1 bladder cancer
PAPMET: cabozantinib vs sunitinib for metastatic papillary RCC
IMMUNOPRESERVE: Immunoradiotherapy for localised MIBC
Please login below to download this issue (PDF)